UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
暂无分享,去创建一个
Aaron Y. Lee | Cecilia S Lee | Cecilia S. Lee | P. Keane | C. Bunce | W. Xing | G. Liew | M. McKibbin | M. Tsaloumas | D. Sim | U. Chakravarthy | C. Egan | R. Antcliff | A. Tufail | R. Johnston | C. Bailey | L. Downey | T. Butt | S. Natha | T. Akerele | R. Khan | A. Varma | K. Mandal | Vineeth Kumar | M. Mckibbin
[1] C. Mallen,et al. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data , 2014, BMC Ophthalmology.
[2] C. Bunce,et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. , 2014, Ophthalmology.
[3] Judy E. Kim,et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1. , 2014, Contemporary clinical trials.
[4] Amitha Domalpally,et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.
[5] Kang Zhang,et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.
[6] Q. Mohamed,et al. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK , 2013, British Journal of Ophthalmology.
[7] B. Kirchhof,et al. Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.
[8] P. Vécsei-Marlovits,et al. The significance of early treatment of exudative age-related macular degeneration: 12 months’ results , 2012, Wiener klinische Wochenschrift.
[9] P. Keane,et al. Evaluation of age-related macular degeneration with optical coherence tomography. , 2012, Survey of ophthalmology.
[10] Sascha Fauser,et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.
[11] E. Souied,et al. [Epidemiology of age related macular degeneration]. , 2009, Journal francais d'ophtalmologie.
[12] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[13] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[14] Sanjay Sharma,et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. , 2005, Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie.
[15] Michael Stur,et al. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. , 2005, Survey of ophthalmology.
[16] R. Klein,et al. Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.
[17] T. Peto,et al. The epidemiology of age-related macular degeneration. , 2004, American journal of ophthalmology.
[18] A. Rudnicka,et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? , 2003, The British journal of ophthalmology.
[19] F. Ferris,et al. Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.
[20] Andrew J. Lotery,et al. Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration , 2012, PharmacoEconomics.
[21] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[22] G. Brown,et al. Utility values and age-related macular degeneration. , 2000, Archives of ophthalmology.
[23] G. Yılmaz,et al. Clinical Interventions in Aging Dovepress Visual Outcome of Intravitreal Ranibizumab for Exudative Age-related Macular Degeneration: Timing and Prognosis Çag ˘la Sarıtürk , 2022 .
[24] I. Aslanides,et al. Single-step transepithelial ASLA (SCHWIND) with mitomycin-C for the correction of high myopia: long term follow-up , 2014, Clinical ophthalmology.